
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Biocompatible plastics support the body's natural healing processes without provoking harmful or allergic reactions. Due to their chemical inertness, which prevents them from interacting with the environment of the human body, they are able to achieve this, allowing the body to absorb these devices without negative consequences. Mechanical, thermal, chemical, systemic injection, intracutaneous, and implantation tests are all used to evaluate these devices.
A plastic component cannot be certified until all of these are completed. PVC and Polyethylene in medical grade, PEEK, Polycarbonate, Ultima PEI, Polysulfides, Polypropylene, and Polyurethane are typical materials for biocompatible applications.
The Global Biocompatible plastics market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
High levels of biological system inertness are offered by the Eslinger Medical Grade (MT) partially finished plastics. Tests for biocompatibility that are appropriate for the situation and more details on the raw materials can demonstrate this. With the help of these details, the laborious process of gathering data for the downstream value chain is sped up.
Depending on the specific application, test results for biocompatibility on raw materials and semi-finished plastics may be transposed on downstream products to save money and time.
In order to enable a streamlined evaluation procedure for medical devices, Eslinger has produced a biocompatibility declaration that is comprehensive and contains all relevant data.
The certificate also guarantees traceability, which provides a financially advantageous documentation process. It is reassuring to know that the ideal material was picked early in the product development process when using a biocompatible Eslinger medical grade material. For a variety of engineering and high performance plastics, Eslinger offers medical grade materials (MT).
This enables customers to choose the material that is most suited for their applications and devices without the decision being constrained by a restrictive filter. Every order for Eslinger MT plastics comes with a declaration of biocompatibility.
All semi-finished stock products intended for medical use (MT portfolio) meet the criteria for biocompatibility for the use they are intended for with less than 24 hours of contact. With the order-related issuance, they guarantee that the semi-finished product and the raw material utilized can be traced back to the customer's order.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |